Many xenobiotic compounds exert their actions through the release of free radicals and related oxidants [1, 2] , bringing about unwanted biological effects [3] . Indeed, oxidative events may play a significant role in tobacco toxicity from cigarette smoke. Here, we demonstrate the direct in vitro release of the free radical nitric oxide (
INTRODUCTION
Whether generated intracellularly, or exogenously delivered, the diatomic free radical nitric oxide (
• NO) is rapidly disseminated throughout the body, affecting key biological processes. Supra-physiologic • NO concentrations favor the formation of a potent biological oxidant; peroxynitrite (ONOO -), the reaction product of
• NO and the oxygen-centered free radical, superoxide, O 2
•− [4] .
Numerous cytotoxic lesions have been attributed to ONOO -, including lipid peroxidation, protein thiol oxidation, inhibition of Fe-S enzyme systems, and oxidative DNA lesions such as strand breaks and base modifications, to name some [4] [5] [6] .
Of the over 30 carcinogens found in tobacco, the nitrosamine compounds, nitrosonornicotine (NNN) and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) are thought to be the major contributors to the carcinogenic activity of nicotine and tobacco [7, 8] . NNN and NNK are formed during the curing, aging, and fermentation of tobacco, as well as during nicotine metabolism. Already,
• NO generation has been demonstrated in cigarette smoke [9] . The structural similarities between NNN and NNK, and other known therapeutic and experimental • NO-releasing compounds suggest that these nitrosamines may be novel • NO-releasing agents in tobacco [10, 11] . Indeed, NNK has been shown to generate DNA strand breaks, as well as induce the formation of DNA adducts, including methylated DNA [12, 13] . Here, we demonstrate, using both direct and indirect methods, the in vitro release of • NO from extracts and components of smokeless tobacco, including nicotine, and the nitrosamine metabolites of tobacco, nitrosonornicotine (NNN) and 4-(methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone (NNK).
MATERIALS AND METHODS

Tobacco xenobiotic preparations
Experiments were conducted in phosphate-buffered saline (PBS) at pH 7.4 or unstimulated human saliva obtained from healthy, non-users of tobacco, without clinical evidence of periodontal disease. We estimated the mass of a "pinch" of smokeless tobacco to be approximately 2.2 g, and suspended this (Copenhagen ® brand, National Tobacco Co., Ltd., Pointe Claire, QB) in 4.4 mL of PBS or saliva. The amount of nicotine in this preparation has been determined previously to be 12 ± 0.7 mg per g tobacco [8] . Therefore, 26.4 mg of nicotine (Sigma Chemical Co., St Louis, MO) was used for the assays. Ten mg of NNN and NNK (Midwest Research Institute, St. Louis, MO) was used for • NO determinations. Each of these prepared solutions was purged with argon gas, and incubated at 37ºC for 20 min in an air-tight container before being assayed for
• NO.
EPR spin trapping
Each xenobiotic preparation was incubated with a 10 mM solution of the iron (II)/N-methyl-D-glucamine dithiocarbamate, Fe 2+ (MGD) 2 , spin trap at 37ºC for 20 min so that the final concentration of the spin trap was 1 mM [14] . Each 500 µL solution was then quickly transferred to an argon-purged flat cell, and EPR spectra were collected with a Bruker (Billerica, MA, USA) X-band EMX spectrometer operating at 9.75 GHz, receiver gain of 2 x 10 
Chemiluminescent detection
Fifty µL of each xenobiotic solution was injected into a Sievers 280 Nitric Oxide Analyzer (Boulder, CO, USA) containing a reducing agent, KI, potassium iodide (5.9 mM) in glacial acetic acid [14] . Standardization was accomplished by injecting various concentrations of a standard solution of NaNO 2 into the same reducing environment. Samples were run in triplicate. 2 . This species yields a characteristic threeline EPR spectrum with an inter-peak hyperfine splitting value, a N , of 12.4 G and an isotropic nuclear g value, g iso , of 2.04, both of which are characteristic of trapped • NO [14] (Figure 1 ). We observed unstimulated • NO release from smokeless tobacco extract and NNN, and weak release from NNK in PBS. Free
RESULTS AND DISCUSSION
• NO was not detected from pure nicotine under these conditions. However, given its chemical structure, we would not expect to observe an EPR signal from nicotine. When these experiments were performed in human saliva under identical conditions, we observed substantially stronger EPR signals. We believe this increased signal strength to be derived, in part, from the reduction of salivary NO 2 − by cytochrome cd 1 nitrite reductase found in some salivary bacteria [15, 16] . Under these conditions, we observed a substantial EPR signal from nicotine in human saliva. The intensity of this signal suggests there to be substantial biotransformation of 1  61  121  181  241  301  361  421  481  541  601  661  721  781  841  901  961  1021 nicotine, facilitating the release of [14] . The results of these experiments are summarized in Table 1 . Briefly, phosphate buffered saline and human saliva generate 5 ± 1 µM and 38 ± 17 µM
• NO, respectively, while extracts of smokeless tobacco in these fluids produced 1100 ± 50 µM release from these compounds is notable. Although others have reported free radical, and in particular, O 2
•-production in cells exposed to smokeless tobacco and nicotine [17] [18] [19] , none identified free radical release directly from smokeless tobacco xenobiotics. Tobacco xenobiotics represent as yet unrecognized sources of
• NO in the body. Indeed tobaccoderived
• NO may have widespread biological implications for tobacco users. Our results also lead us to speculate that • NO and nitrosative events may play a role in tobacco toxicity in the oral cavity and aerodigestive tract.
